EMA Gives Advice On Biomarker That Could Speed Up AML Drug Development
Traditional Clinical Endpoint Of Survival Has Made Acute Myeloid Leukemia Trials Lengthy
The European Medicines Agency has issued a “letter of support” to encourage ongoing efforts by an industry-led consortium to establish measurable residual disease as a surrogate efficacy endpoint in clinical studies of patients with acute myeloid leukemia.
